NFKB1 and lung adenocarcinoma: The results obtained from tumor tissue mirrored bortezomib-induced suppression of the expression of these mediators by LLC cells in vitro (Figure 1B) and, in addition to the TUNEL results described above, served as biomarkers of efficient in vivo suppression of NF-κB activation of mouse lung adenocarcinoma.